Investigating Alzheimer's disease biomarkers in patients after COVID-19 infection
Alzheimer’s Disease Related Biomarkers following SARS-CoV-2 Infection
This study is looking at how COVID-19 might affect thinking and memory in older adults aged 60 and up, especially those who have noticed new memory problems after getting sick, to see if it could increase the risk of Alzheimer's and related conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11057695 on NIH RePORTER |
What this research studies
This research focuses on understanding how COVID-19 infection may lead to cognitive impairment and increase the risk of Alzheimer's Disease and related dementias in older adults. The study will enroll patients aged 60 and above, particularly those who have experienced new cognitive symptoms following their COVID-19 infection. Researchers will analyze blood samples for biomarkers associated with neurodegeneration and cognitive decline, as well as conduct cognitive assessments over time to track changes. By correlating these findings with inflammation markers, the study aims to identify potential predictors of Alzheimer's disease progression in this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 60 and older who have tested positive for SARS-CoV-2 and are experiencing new cognitive symptoms.
Not a fit: Patients who are younger than 60 or those who have not experienced cognitive symptoms following COVID-19 infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to early identification and intervention strategies for Alzheimer's disease in patients recovering from COVID-19.
How similar studies have performed: Previous research has indicated a link between COVID-19 and neurological disorders, suggesting that this approach may yield valuable insights into Alzheimer's disease risk.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Wisniewski, Thomas M — New York University School of Medicine
- Study coordinator: Wisniewski, Thomas M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.